Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Drug Device Combination Market Size Changed, over the years?

In recent times, the market size of the drug device combination has experienced a swift expansion. The market, which is expected to be worth $131.01 billion in 2024, is predicted to surge to $145.29 billion in 2025, marking a compound annual growth rate (CAGR) of 10.9%. The historic growth rate can be attributed to a myriad of factors, including the rise in medical innovation, an increase in chronic diseases, the adoption of patient-centric approaches, advancements in biologics, the challenges associated with monotherapy, and clinical needs.

How Much Will the Drug Device Combination Market Be Worth in 2029?

The size of the market for drug-device combinations is predicted to experience a swift expansion in the coming years, reaching a valuation of $227.94 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 11.9%. The escalation in the prediction period can be credited to a multitude of factors such as the empowerment and involvement of patients, the digital overhaul in healthcare, expansion in the global market, the advent of innovative therapies, and healthcare that focuses on value. The forecast period is also expected to witness key trends such as advancements in therapeutics, management of complex diseases, care that revolves around patients, innovations in technology and supportive regulatory measures.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8206&type=smp

Which is the Largest Company in the Drug Device Combination Market?

Major companies operating in the drug device combination market are The 3M Company, Abbott India Ltd., Biotronik SE & Co. KG, Boston Scientific Corporation, Medtronic PLC, Ypsomed Holding AG, Micron Biomedical Inc., MetP Pharma AG, Sonceboz SA, Lepu Medical Technology (Beijing) Co. Ltd., Eitan Medical Ltd., Vaxess Technologies Inc., Subcuject Aps, Allergan PLC, Terumo Corporation, Stryker Corporation, Becton Dickinson and Company, Zimmer Biomet Holdings Inc., MediPrint Ophthalmics, Arrow International Inc., Alcon Inc., W. L. Gore & Associates Inc., Cook Medical LLC, Pinnacle Biologics Inc.

What Are the Main Market Drivers in the Drug Device Combination Industry?

The drug-device combination market is expected to be propelled by the escalating occurrence of chronic diseases. The term ‘chronic disease’ denotes illnesses that last for a year or more, hinder daily activities, and necessitate ongoing medical treatment, or both. Examples of such diseases are heart disease, diabetes, etc. Drug-device combinations are therapeutic and diagnostic tools that aid in efficient treatment of individuals with chronic diseases. For example, a report by the World Health Organization, a UN specialized agency for maintaining global health, stated in 2022 that diabetes afflicted over 420 million persons worldwide. These figures are projected to rise to 578 million and 700 million in 2030 and 2045, respectively. Therefore, the escalating prevalence of chronic diseases is fuelling the expansion of the drug-device combination market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8206&type=smp

How Is the Drug Device Combination Market Segments Structured?

The drug device combination market covered in this report is segmented –

1) By Product: Auto-Injector, Microneedle Patch, Digital Pill, Smart Inhaler, Drug Delivery Hydrogels, Drug-Eluting Lens, Other Products

2) By Distribution Channel: Direct Tender, Retails Sales, Other Distribution Channels

3) By Application: Orthopedic Diseases, Respiratory Diseases, Diabetes, Oncology, Cardiovascular Diseases, Other Applications

4) By End User: Clinics, Hospitals, Home Care Settings, Ambulatory Care Centers, Other End Users

Subsegments:

1) By Auto-Injector: Pre-Filled Auto-Injectors, Reusable Auto-Injectors

2) By Microneedle Patch: Dissolving Microneedle Patches, Coated Microneedle Patches

3) By Digital Pill: Ingestible Sensors, Smart Capsules

4) By Smart Inhaler: Metered-Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)

5) By Drug Delivery Hydrogels: Injectable Hydrogels, Topical Hydrogels

6) By Drug-Eluting Lens: Contact Lenses, Intraocular Lenses

7) By Other Products: Transdermal Patches, Implantable Drug Delivery Systems

What Strategic Trends Are Transforming the Drug Device Combination Market?

Leading corporations in the drug combination device market are introducing innovative products, like Trelegy Ellipta, to maintain their market dominance. Trelegy Ellipta, a pioneering single-inhaler triple therapy tool, facilitates the precise delivery of medication doses to the lungs. For instance, in April 2022, the UK-based pharmaceutical and biotechnology firm, GSK, rolled out Trelegy Ellipta. These inhalers, besides being compact and easily portable, are utilized in managing chronic obstructive pulmonary disease (COPD) and asthma. Ellipta inhalers, used for combination therapy, can accommodate up to three different drugs in their foil packaging. Trelegy Ellipta, a drug combination implement, merges three active components – fluticasone furoate, umeclidinium, and vilanterol into a single inhaler. Hence, Trelegy Ellipta serves to improve patient management of respiratory diseases through its comprehensive delivery system.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/drug-device-combination-global-market-report

Which Global Regions Offer the Highest Growth in the Drug Device Combination Market?

North America was the largest region in the drug-device combination market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug device combination market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8206

This Report Delivers Insight On:

1. How big is the drug device combination market, and how is it changing globally?

2. Who are the major companies in the drug device combination market, and how are they performing?

3. What are the key opportunities and risks in the drug device combination market right now?

4. Which products or customer segments are growing the most in the drug device combination market?

5. What factors are helping or slowing down the growth of the drug device combination market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model